TECH Stock: Bio-Techne Corporation Stock Price, Analysis & Insights
Get live tech stock price $59.92, comprehensive Bio-Techne Corporation stock analysis, charts, news, and expert forecast. Real-time tech stock data and investment insights.
Loading chart...
Company Overview
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Company Information
- CEO
- Kim Kelderman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 3100
Contact Information
- Website
- https://www.bio-techne.com
- Address
- 614 McKinley Place N.E.
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 122.3)
✓ Higher growth potential with elevated volatility (Beta: 1.47)
Business Model & Strategy
Bio-Techne Corporation operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Kim Kelderman, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Bio-Techne Corporation competes in the Biotechnology within the broader Healthcare. With 9.4 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Bio-Techne Corporation provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Bio-Techne Corporation should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Bio-Techne Corporation shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Bio-Techne Corporation
- ⚠Investors should consider how Bio-Techne Corporation fits within their overall portfolio allocation
- ⚠Premium valuation (P/E: 122.3) requires strong growth to justify
Market Cap
9.39B
P/E Ratio
122.29
Beta
1.47
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 9.39B market capitalization
- Trading Volume: 890.62K shares traded today
- Price Range: 52-week range of $46.01 - $79.28
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Bio-Techne Corporation
Bio-Techne Corporation (TECH) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 9.39B, the company represents a significant player in its market. The stock is currently trading at $59.92 with a negativedaily change of 1.37%.
The company's 3100 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 122.29, beta of 1.47, and 52-week price range from $46.01 to $79.28when evaluating investment opportunities.
Why Invest in Bio-Techne Corporation?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Kim Kelderman
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.